Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 4 of these applications claim priority to application 17/925,813, filed Nov 16, 2022. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,945,849 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | Othair Prothena Limited | In force | Medium confidence | ||
| US 11,952,406 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | Othair Prothena Limited | In force | Medium confidence | ||
| US 11,965,005 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | Othair Prothena Limited | In force | Medium confidence | ||
| US 12,247,056 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease In force · Medium confidence | Othair Prothena Limited | In force | Medium confidence | ||
| Application 17/925,813 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease Pending Not granted | Prothena Biosciences Inc. | Pending | Not granted | ||
| Application 19/064,783 | Multi-Epitope Vaccine for the Treatment of Alzheimer's Disease Pending Not granted | Othair Prothena Limited | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
4 of these are in force and held by Othair Prothena Limited.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.